+ 34 986 812 316

Cancer Epigenetics Society
Werdertorgasse 12/3/6, 1010 Vienna

cancer, epigenetics, epigenomics, databases, chemoinformatics


The Cancer Epigenetics Society is interested in all models relevant to epigenetics research


The Cancer Epigenetics Society is interested in all techniques relevant to epigenetics research

Collaborations outside COST

Genomic Sciences and Precision Medicine Center, Milwaukee, WI, USA National Autonomous University of Mexico, Mexico Union for International Cancer Control, Geneva, Switzerland

Short description of ongoing research projects

Current projects include development and expansion on searchable epigenetics drug databases. Additional projects include intergration of on-site R-environment bioinformatic analysis of epigenetics drugs activity bioprofiling.

  1. Liersch-Löhn B et al. Differential protein expression and oncogenic gene network link tyrosine kinase Ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. International Journal of Cancer 138: 1220-1231, 2016.
  2. Bennani-Baiti IM. Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer. Breast Cancer Research 14: 112, 2012.
  3. Bennani-Baiti IM. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics 3: 715-732, 2011.
  4. Bennani-Baiti IM et al., Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 43: 1300-1307, 2012.
  5. Richter GHS et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuroectodermal differentiation. Proc. Natl. Acad. Sci. USA. 106: 5324-5329, 2009.
Other activities of potential interest to others

Executive Editor of Cancer Epigenetics and of Clinical Cancer Epigenetics journals series.

Cost UE